Table 1 General characteristics of RAI-R DTC patients

Age

 < 55

54 (49.1%)

 ≥ 55

56 (50.9%)

Mean ± SD (min – max)

53.6 ± 14.25 (17 – 79)

Gender

Male

17 (15.5%)

Female

93 (84.5%)

Female/Male ratio

1/5.5

Histological subtype

Papillary

96 (87.3%)

Aggressive variant and follicular

14 (12.7%)

ETE of the primary tumor

No

73 (66.4%)

Yes

27 (24.5%)

No determined

10 (9.1%)

Stage at initial DTC diagnosis

I – II

80 (72.7%)

III—IV

27 (24.6%)

No determined

3 (2.7%)

Cumulative RAI activities administrated (mCi)

 ≤ 600

94 (85.5%)

 > 600

16 (14.5%)

Mean ± SD

405 ± 228.8 (80 – 1300)

Number of ¹³¹I therapy course (s) before [¹⁸F]FDG PET/CT

2.97 ± 1.44 (1 – 8)

Stimulated serum Tg before [¹⁸F]FDG PET/CT (ng/ml) (median, range)

177.9 (10.7 – 5982)

Metabolic parameters of

[¹⁸F]FDG PET/CT (median, quartiles)

SUVmax (g/ml)

6.39 (3.24 – 11.62)

SUVmean (g/ml)

3.68 (2.39 – 6.07)

SULpeak (g/ml)

3.14 (1.89 – 7.19)

TLG (g/ml x cm³)

4.23 (0.93 – 23.54)

MTV (cm³)

1.24 (0.34 – 4.95)

Median of follow up (months)

40 (6.57 – 82.5)

Progressive disease

58 (52.7%)